Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
NCT ID: NCT01101945
Last Updated: 2010-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
339 participants
INTERVENTIONAL
2007-07-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
NCT00865592
Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus
NCT00690638
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
NCT01089790
Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
NCT00998686
Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment
NCT00958269
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dutogliptin
400 mg QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current treatment of Type 2 diabetes mellitus in accordance with product labeling with metformin, or thiazolidinedione (TZD), or metformin + TZD
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Phenomix
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Phenomix Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fullerton, California, United States
Long Beach, California, United States
Orange, California, United States
San Diego, California, United States
Kissimmee, Florida, United States
Melbourne, Florida, United States
New Port Richey, Florida, United States
Gurnee, Illinois, United States
Wichita, Kansas, United States
Kansas City, Missouri, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Berlin, New Jersey, United States
Margate City, New Jersey, United States
Trenton, New Jersey, United States
Charlotte, North Carolina, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Oklahoma City, Oklahoma, United States
Medford, Oregon, United States
Warminster, Pennsylvania, United States
Columbia, South Carolina, United States
Greer, South Carolina, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Norfolk, Virginia, United States
Cuidad Autonoma de Buenos Aires, Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
Lanús Este, Buenos Aires, Argentina
Morón, Buenos Aires, Argentina
Quilmes, Buenos Aires, Argentina
Corrientes, Corrientes Province, Argentina
Calgary, Alberta, Canada
Red Deer, Alberta, Canada
Mount Pearl, Newfoundland and Labrador, Canada
St. John's, Newfoundland and Labrador, Canada
Etobicoke, Ontario, Canada
London, Ontario, Canada
Samia, Ontario, Canada
Toronto, Ontario, Canada
Cornwall, Prince Edward Island, Canada
Mirabel, Quebec, Canada
Montreal, Quebec, Canada
Ellisbridge, Ahmedabad, India
Banjara Hills, Hyderabad, India
Punjagutta, Hyderabad, India
Pune, Maharashtra, India
Tardeo, Mumbai, India
Dhantoli, Nagpur, India
Chennai, Tamil Nadu, India
Guadalajara, Jalisco, Mexico
Mexico City, Mexico City, Mexico
Morelia, Michoacán, Mexico
Monterrey N. L., Nuevo León, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHX1149-PROT202E
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.